Literature DB >> 31183651

Bone Marrow Multipotent Mesenchymal Stromal Cells in Patients with Diffuse Large B-Cell Lymphoma.

E A Fastova1, A U Magomedova2, N A Petinati2, N V Sats2, N M Kapranov2, Yu O Davydova2, N I Drize2, S K Kravchenko2, V G Savchenko2.   

Abstract

In diffuse large B-cell lymphoma, bone marrow involvement is rarely diagnosed. We compared the properties of bone marrow stromal progenitor cells and the concentration of fibroblast CFU in patients with diffuse large B-cell lymphoma without bone marrow involvement and in healthy donors. It was found that the properties of multipotent mesenchymal stromal cells in patients in the debut of the disease differed considerably from those in healthy donors. In particular, the total cell production in patients was significantly higher than in donors. In multipotent mesenchymal stromal cells of patients, some cell parameters were changes; the mean fluorescence intensity of the adhesion molecule ICAM1 on the cell surface was increased. The mean fluorescence intensity of mesenchymal stromal cell markers (HLA-ABC, CD73 and CD90) was significantly elevated. The relative expression of BMP4, MMP2, FGFR1, and ICAM1 genes in mesenchymal stromal cell was reduced, while the expression of FGFR2 gene was enhanced. Despite the absence of proven involvement of the bone marrow, the properties of mesenchymal stromal cells, the components in the stromal microenvironment niche regulating hemopoiesis are altered in patients with diffuse large B-cell lymphoma.

Entities:  

Keywords:  fibroblast colony-forming units; mean fluorescence intensity; multipotent mesenchymal stromal cells; relative level of gene expression

Mesh:

Substances:

Year:  2019        PMID: 31183651     DOI: 10.1007/s10517-019-04480-6

Source DB:  PubMed          Journal:  Bull Exp Biol Med        ISSN: 0007-4888            Impact factor:   0.804


  2 in total

1.  Differences in Protein Secretion by Multipotent Mesenchymal Stromal Cells Effective and Ineffective in the Prevention of Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  N A Petinati; N I Drize; G P Arapidi; V O Shender; M A Lagar'kova; L A Kuz'mina; E N Parovichnikova; V G Savchenko
Journal:  Bull Exp Biol Med       Date:  2022-05-27       Impact factor: 0.804

2.  Changes in Bone Marrow Stromal Progenitor Cells in Patients with Hematoblastosis at the Onset of the Disease.

Authors:  N A Petinati; I N Shipounova; E A Fastova; A U Magomedova; S K Kravchenko; E Yu Chelysheva; O A Shukhov; A G Turkina; N V Sats; N I Drize; E N Parovichnikova; V G Savchenko
Journal:  Bull Exp Biol Med       Date:  2021-09-20       Impact factor: 0.804

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.